Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

de la Camara R et al. – Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. The authors assessed, from the perspective of the Spanish National Health Service, the cost–effectiveness of posaconazole vs fluconazole in preventing IFI. Compared with fluconazole, posaconazole prophylaxis is a cost–effective strategy for the prevention of IFI in patients with GVHD.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address